Registry Study for Talimogene Laherparepvec

A registry study is to evaluate the overall survival, use of subsequent anti-cancer therapy,
and the long-term safety of subjects who have received at least one dose of talimogene
laherparepvec on an Amgen or BioVEX-sponsored clinical trial for any tumor type. Follow-Up
will occur every 3 months.

Inclusion Criteria:

All subjects must provide informed consent prior to initiation of any study activities.

All subjects must have received at least one dose of talimogene laherparepvec on an Amgen
or BioVEX-sponsored clinical trial for any tumor type and must have discontinued treatment
and participation, including long-term follow-up (if applicable) in that trial.

Exclusion Criteria:

Subjects currently receiving talimogene laherparepvec in Amgen or BioVEX-sponsored clinical
trial.

Subject currently participating, including for long-term follow-up (if applicable), in
other Amgen-sponsored talimogene laherparepvec clinical trial.